{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:03Z","timestamp":1792794723193,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vifor Fresenius Medical Care Renal Pharma AG","id":[{"id":"https:\/\/ror.org\/05rs7tq63","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Key challenges in the management of ANCA-associated vasculitis (AAV) include the need to achieve more rapid and sustained remission, reduce exposure to glucocorticoids (GC) and reliably monitor and predict treatment response. Clinical trials in patients receiving rituximab or cyclophosphamide for AAV show that the adjunctive use of avacopan (a novel complement 5a receptor 1 [C5aR1] antagonist) for up to 1\u2009year enables sustained AAV remission, considerable reductions in GC exposure, and greater recovery of kidney function, especially in patients with acute kidney injury. Additional real-world evidence suggests avacopan can be used to replace GC in patients with GC toxicity and supports the use of avacopan in AAV patients with rapidly progressing glomerulonephritis, pulmonary hemorrhage and\/or refractory AAV. Future studies are needed to investigate the benefits of extending avacopan treatment beyond 1\u2009year and in specific populations.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaf581","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:13:28Z","timestamp":1761830008000},"page":"i20-i26","source":"Crossref","is-referenced-by-count":4,"title":["Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David","family":"Jayne","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Cambridge and Addenbrooke\u2019s Hospital , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"2026010901514400800_keaf581-B1","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.3390\/ijms21197319","article-title":"Immunopathogenesis of ANCA-associated vasculitis","volume":"21","author":"Kronbichler","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026010901514400800_keaf581-B2","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/jcm10071446","article-title":"ANCA-associated vasculitis: an update","volume":"10","author":"Almaani","year":"2021","journal-title":"J Clin Med"},{"key":"2026010901514400800_keaf581-B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026010901514400800_keaf581-B4","doi-asserted-by":"publisher","author":"Hellmich","DOI":"10.1093\/rheumatology\/keaf517"},{"key":"2026010901514400800_keaf581-B5","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes AVWG","year":"2024","journal-title":"Kidney Int"},{"key":"2026010901514400800_keaf581-B6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.40776","article-title":"Effect of disease activity at three and six months after diagnosis on long-term outcomes in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Gopaluni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026010901514400800_keaf581-B7","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"Corrigendum to \u201cKDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis","volume":"105","author":"KDIGO","year":"2024","journal-title":"Kidney Int"},{"key":"2026010901514400800_keaf581-B8","doi-asserted-by":"crossref","first-page":"e018748","DOI":"10.1136\/bmjopen-2017-018748","article-title":"Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial","volume":"7","author":"Furuta","year":"2017","journal-title":"BMJ Open"},{"key":"2026010901514400800_keaf581-B9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","article-title":"Rituximab for treatment of severe renal disease in ANCA associated vasculitis","volume":"29","author":"Geetha","year":"2016","journal-title":"J Nephrol"},{"key":"2026010901514400800_keaf581-B10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2026010901514400800_keaf581-B11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2026010901514400800_keaf581-B12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010901514400800_keaf581-B13","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"2026010901514400800_keaf581-B14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010901514400800_keaf581-B15","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026010901514400800_keaf581-B16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2026010901514400800_keaf581-B17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026010901514400800_keaf581-B18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/rheumatology\/keaa541","article-title":"Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models","volume":"60","author":"McClure","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026010901514400800_keaf581-B19","doi-asserted-by":"crossref","first-page":"sfae379","DOI":"10.1093\/ckj\/sfae379","article-title":"Albuminuria after induction treatment and kidney prognosis in ANCA-associated glomerulonephritis","volume":"18","author":"Chalkia","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026010901514400800_keaf581-B20","article-title":"Change in albuminuria in patients with ANCA-associated vasculitis treated with avacopan [abstract]","volume":"75","author":"Geetha","year":"2023","journal-title":"Arthritis Rheumatology"},{"key":"2026010901514400800_keaf581-B21","doi-asserted-by":"publisher","first-page":"keaf539","DOI":"10.1093\/rheumatology\/keaf539","article-title":"Targeting the complement system in ANCA-associated vasculitis management","author":"de Groot","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026010901514400800_keaf581-B22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ndt\/gfae069.135","article-title":"Avacopan versus prednisone taper in newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis in the ADVOCATE trial","volume":"39","author":"Kronbichler","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026010901514400800_keaf581-B23","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1093\/rheumatology\/keaf122","article-title":"Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial","volume":"64","author":"Geetha","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026010901514400800_keaf581-B24","doi-asserted-by":"crossref","first-page":"e11795","DOI":"10.1002\/acr2.11795","article-title":"Treatment with avacopan in patients with respiratory tract manifestations of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Specks","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"2026010901514400800_keaf581-B25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1681\/ASN.2024cvqgw1q0","article-title":"General, nervous system, eye, and skin involvement in the phase 3 trial of avacopan for the treatment f ANCA-associated vasculitis","volume":"35","author":"Geetha","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026010901514400800_keaf581-B26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026010901514400800_keaf581-B27","author":"EMA","year":"2025"},{"key":"2026010901514400800_keaf581-B28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000543159","article-title":"Practical management of ANCA-associated vasculitis: a clinician\u2019s perspective","volume":"5","author":"Stacey","year":"2025","journal-title":"Glomerular Dis"},{"key":"2026010901514400800_keaf581-B29","doi-asserted-by":"crossref","first-page":"100858","DOI":"10.1016\/j.xkme.2024.100858","article-title":"Glucocorticoid minimization in anti-neutrophil cytoplasmic antibody-associated vasculitis: an international survey of clinicians","volume":"6","author":"Massicotte-Azarniouch","year":"2024","journal-title":"Kidney Med"},{"key":"2026010901514400800_keaf581-B30","article-title":"Real-world use of avacopan for ANCA-associated vasculitis beyond 52 weeks","volume":"76","author":"Ford","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026010901514400800_keaf581-B31","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/ndt\/gfae069.1249","article-title":"Safety and effectiveness of avacopan beyond 52 weeks: experience to date in the Early Access Program (EAP)","volume":"39","author":"Alberici","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026010901514400800_keaf581-B32","author":"Francis","year":"2024"},{"key":"2026010901514400800_keaf581-B33","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.ekir.2023.05.017","article-title":"Avacopan in patients with rapidly progressive glomerulonephritis requiring dialysis","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026010901514400800_keaf581-B34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/ndt\/gfae020","article-title":"Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrage","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026010901514400800_keaf581-B35","doi-asserted-by":"crossref","first-page":"i15","DOI":"10.1093\/rheumatology\/keae663","article-title":"Emerging targeted therapies in ANCA-associated vasculitis","volume":"64","author":"Jayne","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026010901514400800_keaf581-B36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","article-title":"B cell therapy in ANCA-associated vasculitis: current and emerging treatment options","volume":"14","author":"McClure","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2026010901514400800_keaf581-B37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/ndt\/gfad237","article-title":"ANCA-associated vasculitis-treatment standard","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026010901514400800_keaf581-B38","doi-asserted-by":"crossref","first-page":"sfae389","DOI":"10.1093\/ckj\/sfae389","article-title":"Top ten tips in managing ANCA vasculitis","volume":"18","author":"Tan","year":"2025","journal-title":"Clin Kidney J"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf581\/65132175\/keaf581.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/Supplement_1\/i20\/65132175\/keaf581.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/Supplement_1\/i20\/65132175\/keaf581.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:51:54Z","timestamp":1767941514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/65\/Supplement_1\/i20\/8313532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":38,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf581","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,3]]}}}